Skip to content

VIVAPHARMA

Active
Private limited companyfounded 20196 yrs activeWaverse steenweg 1585, 1160 Oudergem, BelgiumKBO/BCE: BE 0740.481.964
Summary

VIVAPHARMA has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €126,780 and a net result of €118,241. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 68% of 4652 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisWatch ReportCompare
VIVAPHARMAActiveChecked score 96/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€236,296total assets 2025
Equity
€126,780
Profit
€118,241
Financial health
96 Excellent Checked score 2025
Bankruptcy chance 12 m
0.1%
Structure
Parent
ERYA PHARMA SRL
Accounts 53 d early0 of 3 deeds read
Why 96- Sector Retail trade (NACE 47)- Founded in 2019+ Liquidity: current ratio 3.12, cash €102,103+ Equity €126,780 (53.7% of total assets)Show the evidence

Checked score

Score 2025
96 / 100
Excellent
Probability in this band: under 0.55%
Better than 88% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Strong
Solvency 79+50
equity 53.7% of total assets
Liquidity 90+47
short-term debt 26.5% · cash 43.2%
Profitability 100=
return on assets 50.0%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.7% (39,919 companies)
Last 24 months 11-2024: 2.4%highest value 12-2024: 2.3%▼ -1.7% vs 11-2024 01-2025: 2.1%▼ -7.5% vs 12-2024 02-2025: 2.1%▼ -1.3% vs 01-2025 03-2025: 2.1%▼ -2.0% vs 02-2025 04-2025: 2.1%▲ +1.9% vs 03-2025 05-2025: 2.2%▲ +4.6% vs 04-2025 06-2025: 2.2%▲ +1.5% vs 05-2025 07-2025: 1.1%▼ -52.8% vs 06-2025 08-2025: 1.0%▼ -2.0% vs 07-2025 09-2025: 1.0%● 0.0% vs 08-2025 10-2025: 1.0%● 0.0% vs 09-2025 11-2025: 1.0%▲ +0.6% vs 10-2025 12-2025: 1.0%▲ +0.2% vs 11-2025 01-2026: 1.0%▼ -2.3% vs 12-2025 02-2026: 1.0%● 0.0% vs 01-2026 03-2026: 0.9%▼ -8.3% vs 02-2026 04-2026: 1.0%▲ +8.2% vs 03-2026 05-2026: 1.0%▼ -3.1% vs 04-2026 06-2026: 1.0%▼ -3.0% vs 05-2026 07-2026: 0.1%▼ -85.5% vs 06-2026lowest value 08-2026: 0.1%● 0.0% vs 07-2026lowest value 09-2026: 0.1%● 0.0% vs 08-2026lowest value 10-2026: 0.1%● 0.0% vs 09-2026lowest value
  • Liquidity: current ratio 3.12, cash €102,103 lowers the probability
  • Equity €126,780 (53.7% of total assets) lowers the probability
  • Sector Retail trade (NACE 47) raises the probability
  • Founded in 2019 raises the probability for this profile
Credit up to €12,000 at 30 days acceptable
Liquidity ample (current ratio 3.12 against 1.13 in 2024; short-term debt: 26.5% and cash: 43.2% of total assets), and 46.3% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 67%, liquidity 91%, profitability 96%, growth against the median 99%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Liquidity: current ratio 3.12, cash €102,103
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
lowers risk · Equity €126,780 (53.7% of total assets)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Sector Retail trade (NACE 47)
In the bankruptcy model this factor raises the probability.
KBO
raises risk · Founded in 2019
In the bankruptcy model this factor raises the probability for this profile.
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline.
NBB · 6 filings
Deviation from the deadline
2025
53 d early
2024
42 d early
2023
49 d early
2022
34 d early
2021
52 d early
2020
54 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 47 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 13 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
03-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · full…
  2. Highest result since 2020net €118,241 ▲41%
  3. Liquidity triplescurrent ratio 3.12

Key points

  • Positive: Equity rose in 2025from €8,539 to €126,780 ▲ 1,385% View
  • Controlled by ERYA PHARMA SRL parent View
  • Positive: Always filed on timeaccounts within the deadline every year 6 years View

By topic

Financials

Fiscal year
2025
Total assets
€236,296
Profit
€118,241
Solvency
53.7%
Total assets▲ 15.9%
Net result
20202025
Go to Financials

Timeline

Events
11
Since
2021
Next accounts
by 31-07-2027
  1. 08-06-2026Annual accounts filed
  2. 31-12-2025Highest result since 2020
  3. 31-12-2025Liquidity triples
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
26-12-2019
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure